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Abstract
Background: Using surrogate biomarkers for disease progression as endpoints in neuroprotective clinical trials may help
differentiate symptomatic effects of potential neuroprotective agents from true slowing of the neurodegenerative process.
A systematic review was undertaken to determine what biomarkers for disease progression in Alzheimer’s disease exist and
how well they perform.
Methods: MEDLINE and Embase (1950–2011) were searched using five search strategies. Abstracts were assessed to identify
papers meriting review in full. Studies of participants with probable Alzheimer’s disease diagnosed by formal criteria were
included. We made no restriction on age, disease duration, or drug treatment. We only included studies with a longitudinal
design, in which the putative biomarker and clinical measure were both measured at least twice, as this is the only
appropriate study design to use when developing a disease progression biomarker. We included studies which attempted
to draw associations between the changes over time in the biomarker used to investigate disease progression and a clinical
measure of disease progression.
Results: Fifty-nine studies were finally included. The commonest biomarker modality examined was brain MRI (17/59, 29%
of included studies). Median follow-up in included studies was only 1.0 (IQR 0.8–1.7) year and most studies only measured
the putative biomarker and clinical measure twice. Included studies were generally of poor quality with small numbers of
participants (median 31 (IQR 17 to 64)), applied excessively restrictive study entry criteria, had flawed methodologies and
conducted overly simplistic statistical analyses without adjusting for confounding factors.
Conclusions: We found insufficient evidence to recommend the use of any biomarker as an outcome measure for disease
progression in Alzheimer’s disease trials. However, further investigation into the efficacy of using MRI measurements of
ventricular volume and whole brain volume appeared to be merited. A provisional ‘roadmap’ to improve the quality of
future disease progression biomarker studies is presented.
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Introduction
The rising prevalence of Alzheimer’s disease, the commonest
neurodegenerative disorder, and the associated financial and social
costs this brings, presents a major challenge to governments of
countries with an ageing population [1]. Given that only
symptomatic treatments for Alzheimer’s disease currently exist,
much research has focused on the development of drugs which
slow or even halt neurodegeneration and, therefore, clinical
progression. However, clinical trials in neurodegenerative disor-
ders have struggled to separate out symptomatic effects of potential
therapeutic agents (e.g. due to increased synaptic acetylcholine)
from true disease-modifying effects. In Alzheimer’s disease, it is
currently not possible to directly measure the number of remaining
cortical neurons in vivo and, therefore, alternative approaches are
required. Clinical assessments in Alzheimer’s disease using scales
to measure cognitive impairment, disability, quality of life, or
global disease severity are affected by symptomatic effects of
therapy and are unable to differentiate this effect from disease-
modification, at least in the short-term.
Various clinical trial designs have been developed to try to
adjust for symptomatic effects of putative neurodegenerative
agents and, therefore, allow clinical rating scales to be used as
endpoints. These include long-term follow up studies of placebo-
treated and active-agent treated patients looking for sustained
divergence, measuring outcomes following a wash-out period, and
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delayed start trial designs [2]. However, analytic and logistical
problems with these trial designs have as yet restricted their use
[3]. An alternative approach, the focus of much primary research,
is the use of a surrogate outcome biomarker as an endpoint in
neuroprotective clinical trials.
Surrogate outcome biomarkers are objectively measured
characteristics of a disease, which act as indicators of the
underlying pathogenic process responsible for disease progression,
including the change in that process following a therapeutic
intervention [4,5]. To allow their use in clinical trials surrogate
outcome biomarkers must have a strong association with a clinical
endpoint or outcome known to measure the effect of a therapeutic
intervention on disease progression, for which the biomarker can
act as a substitute. Surrogate biomarkers for disease progression in
Alzheimer’s disease could shorten the duration of phase III trials
and thereby reduce the cost and time required to get a drug to
market. Unfortunately at present there is not a single accepted
surrogate outcome biomarker for any neurodegenerative disorder.
Much has been written about the features that a biomarker for
disease progression in neurodegenerative disorders, such as
Alzheimer’s disease, should possess [6,7]. The ideal surrogate
biomarker should:
1. Change with neurodegeneration (i.e. degeneration of cortical
neurons);
2. Show an association with the clinical phenotype arising
secondary to this degenerative process;
3. Have a direct association with disease progression, without
intermediate variables;
4. Have robust longitudinal data linking it to disease progression;
5. Not be influenced by symptomatic treatment, but only by a
true change in the neurodegenerative process;
6. Predict long-term changes in disease progression by short-term
changes in the biomarker;
7. Be generalisable to people with differing characteristics (e.g.
age, gender, race);
8. Be continually variable (ideally linearly for simplicity);
9. Be sensitive, reflecting small changes in disease progression;
10. Be quick and cheap to measure, and amenable to blinded
assessment;
11. Be suitable for measurement reliably across different
centres;
12. Be suitable for repeated measurement in the same patient;
13. Be safe and tolerable to the patient.
As Alzheimer’s disease is a complex neurodegenerative disorder
in which many different pathophysiological processes have been
implicated (e.g. tau and amyloid deposition, abnormalities of
cholesterol metabolism, inflammation, oxidative damage and
lysosomal dysfunction) it is not surprising that many different
candidate biomarkers for disease progression in Alzheimer’s
disease have been studied. However, the literature in this area
has never been brought together systematically. We, therefore,
aimed to undertake a systematic review to assess what potential
surrogate biomarkers for disease progression in Alzheimer’s
disease exist, whether any meet the criteria for use in clinical
trials, and if not which looks most promising. We did not aim to
review the literature for diagnostic biomarkers (i.e. those designed
to aid early diagnosis in the pre-motor or motor phase) or
prognostic biomarkers (i.e. those aimed at identifying patients who
progress at different rates).
Given the methodological and statistical weaknesses we
identified in studies of biomarkers for disease progression in
Parkinson’s disease (PD) in a previous systematic review [8], we
aimed to determine whether the same problems were prevalent in
Alzheimer’s disease research. We, therefore, aimed to critique data
from identified disease progression biomarker studies relating to
study design, participant characteristics, and statistical analyses
undertaken, in order to produce guidelines for future studies.
Methods
Following the development of a review protocol, literature
searches were conducted in the databases MEDLINE (1950 to
November 2011) and Embase (1980 to November 2011), using the
OVID search interface. Five separate search strategies, based on
previous searches developed by an experienced information
scientist, were run in each database. The first four were based
on free-text words identified through background reading of
relevant review articles. These searches included potential (1)
blood, (2) urine or cerebrospinal fluid (CSF), (3) imaging and (4)
neurophysiological biomarkers. A fifth search using generic terms
for biomarkers based on index headings was also run in both
databases. For details of the search strategy please see document
S1.
The searches were limited to human studies. Only English
language articles were included, due to lack of resources for
translation. Reference lists of included articles and relevant review
articles were checked to identify any studies which the electronic
search strategy may have missed.
Validation of the electronic search strategy
The electronic search strategy was validated by hand searching
five years of the two journals from which most of the included
articles came: Neurology (1995–1999) and Archives of Neurology
(2001–2005). The number of relevant and irrelevant articles
identified by hand searching and by the electronic search, was
used to calculate the sensitivity and specificity for the electronic
search strategy.
Study selection
A single reviewer examined abstracts retrieved by the electronic
search to identify articles meriting review in full. Full length
articles were then reviewed before data were extracted from
relevant papers. In both stages the inclusion and exclusion criteria
detailed below were applied.
Only studies of participants with probable Alzheimer’s disease
diagnosed by formal criteria [9–13] were included. Studies which
included participants with prodromal Alzheimer’s disease or mild
cognitive impairment (MCI) were only included if progression to
Alzheimer’s disease was confirmed in all participants by clinical
follow-up. No restriction was made on the grounds of participant’s
age, disease duration, or drug treatment.
As emphasised in our previous systematic review of biomarkers
for disease progression in PD [8], a cross-sectional study design, in
which an association between a biomarker and a clinical measure
of disease progression is examined at a single time point in a group
of patients with differing disease severity, is not suitable to examine
for a relationship between the change in a clinical measure and the
change in a biomarker over time within individuals with a
neurodegenerative disorder. We, therefore, limited this review to
studies with a longitudinal design, where the biomarker and
clinical measure were recorded at least twice.
Studies which investigated the efficacy of using a biomarker,
including (but not restricted to) imaging, blood tests, tests of CSF
Biomarkers for Disease Progression in AD
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and neurophysiological tests, to investigate disease progression in
Alzheimer’s disease were included. To qualify for inclusion there
must have been an attempt to assess an association between the
change in a biomarker and the change in a clinical measure of
disease progression over time. Acceptable clinical measures
included measures of cognitive impairment, disability, handicap,
quality of life, and global clinical assessments.
Only studies exploring associations between a biomarker and
the total score from a clinical rating scale, rather than its
subsections, were included. The subsections of most clinical
measures would not be acceptable outcome measures for
neuroprotective trials and, therefore, developing surrogate bio-
markers for them was not felt to be relevant. However, exceptions
were made for the following clinical rating scale subsections, which
may be acceptable outcome measures for disease-modification
trials: Alzheimer’s disease assessment scale cognitive (ADAS-cog)
and non-cognitive (ADAS-noncog) subsections [14]; Blessed
dementia scale change in performance of everyday activities
subsection (Blessed ADL) [15]; CAMCOG memory subsection
[16]. Similarly, only studies examining for associations between
putative biomarkers and global measures of cognition, rather than
individual neuropsychological tests were included. Furthermore,
studies solely examining for associations between biomarkers and
measures of neuropsychiatric impairment were not included, as
depression and behavioural disturbance are not clearly associated
with disease progression in Alzheimer’s disease [17].
Studies examining the relationship between a biomarker and
treatment status, the presence or severity of complications related
to therapy, or duration of illness were excluded. We also excluded
studies which examined for associations between symptomatic
improvement, as measuring by clinical rating scales, and the
change in the level or activity of cholinesterase enzymes in the
blood or CSF following commencement of a cholinesterase
inhibitor. As we wished to develop a biomarker for disease
progression rather than a way of measuring the response to
symptomatic therapy, these studies were not felt to be relevant.
Data extraction
Study methods and results were extracted by a single reviewer,
and to check for accuracy this was performed twice. Data were
extracted, using a data extraction sheet (document S2) relating to
the following: (1) study design including restrictiveness of criteria
for entry into the study; (2) setting; (3) study population, including
number of participants, gender ratio, disease duration at baseline,
baseline measures of disease severity and baseline treatment status;
(4) specific biomarkers investigated; (5) statistical analyses per-
formed; (6) results of statistical analyses of the associations between
the biomarkers and clinical measures of disease severity; (7)
analysis of the effect of drug treatment on the biomarker; (8)
economic analysis of using the biomarker; (9) measures of
suitability and acceptability of the test to patients.
The restrictiveness of the inclusion and exclusion criteria
applied to each study was graded as: none, explicit statement that
only criteria to exclude other causes of dementia were applied;
mild #3 criteria applied (except those described under moderate);
moderate, 4–5 criteria applied or evidence of an attempt to limit
by age, gender, cognitive state, drug therapy for Alzheimer’s
disease (e.g. all de-novo); severe$6 criteria applied; not detailed,
no mention of whether criteria were applied.
Methodological quality
No validated tool to measure the quality of studies investigating
surrogate biomarkers as outcome measures exists. An attempt was,
therefore, made to assess study quality using a quality question-
naire developed in our previous systematic review of biomarkers
for disease progression in PD (table 1).
Table 1. Quality criteria to assess studies examining surrogate biomarkers for disease progression[8].
Question Yes No
(1) Was the primary aim of the study to validate a biomarker for disease progression? 32 54
(2) Did the study detail a scientifically valid reason for choosing the given biomarker for investigation? 59 100
(3) Has the reproducibility of measuring the biomarker in the same centre by different trained personnel, and
between centres, been evaluated?
2 3
(4) Has an assessment of the effect of likely confounding factors (e.g. age, gender, smoking status, and being on
symptomatic treatment) on the measurement of the biomarker been made?
1 2
(5) Has an assessment of the validity and reliability of the criterion (e.g. clinical rating scale) used been made? 54 92
(6a) Was a power calculation undertaken to determine the required number of participants? 3 5
(6b) If a power calculation was undertaken, was the number of participants included appropriate? 1 2
(7) Was the study longitudinal? 59 100
(8) Was the study prospective? 49 83
(9) Was there a sufficient period of follow-up? 26 44
(10) Were the biomarker and clinical measures of disease severity measured on $3 occasions? 7 12
(11) Was measurement of the biomarker blind to participant characteristics? 25 42
(12) Did$75% of participants entering the study complete the full follow-up period? 42 71
(13) Were cases unselected/unbiased (no exclusion criteria)? 16 27
(14) Were associations between the biomarker and clinical measures of disease severity examined for using
appropriate statistical modelling (e.g. linear mixed modelling) with adjustment for confounding factors,
rather than simply correlation analysis?
7 12
(15) Were results of statistical analyses reported in sufficient detail to allow the inclusion of the study results
in a meta-analysis?
14 24
doi:10.1371/journal.pone.0088854.t001
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Most articles did not provide information pertinent to question
five (‘has an assessment of the validity and reliability of the
criterion used been made?’), perhaps because it was assumed that
readers would be aware of the psychometric properties of the
criterion used. We, therefore, scored papers favourably for
question five if they used a criterion examined in the review of
outcome measures in clinical trials in Alzheimer’s disease from the
Canadian Coordinating Office for Health Technology Assessment
(CCOHTA) [18]. Whilst the examination of the properties of a
given clinical outcome measure in this review neither implies
adequate or favourable psychometric assessment, it does at least
indicate that some degree of psychometric assessment has
occurred. Where more than one clinical rating scale was used to
draw associations with a biomarker in a single paper, question five
was marked favourably as long as at least one of the clinical
measures was in the aforementioned review.
With regards to question nine (‘was there a sufficient period of
follow-up?’) we denoted a sufficient period of follow-up in this
review as longer than one year. Although this may be an
insufficient period of follow-up to detect significant disease
progression in Alzheimer’s disease, we hoped this cut-off would
at least help differentiate very short studies from those with longer
periods of follow-up.
Data analysis and synthesis
Given the likelihood that included studies would examine the
relationship of multiple different putative biomarkers with multiple
different clinical measures of disease severity, we were aware that
any data synthesis would be qualitative in nature.
Results
As shown in Figure 1, the electronic searches identified 8234
records. After removing duplicates, 5416 unique records identified
by the electronic search were screened, in addition to a further 22
records identified while performing the hand search or on
reviewing reference lists of relevant review articles and included
articles. The full-text articles of 308 records were then assessed for
eligibility, and of those 249 articles were excluded. Finally data
were extracted from a total of 59 articles.
Hand searching
Hand searching to validate the electronic search strategy
revealed a sensitivity of 60.0% (95% CI 17.0–92.7) and a
specificity of 99.1% (95% CI 98.8–99.3). The number of included
articles identified by the electronic search in both journals within
the chosen time period was small (Archives of Neurology n= 2,
Neurology n= 1). The low sensitivity related to the finding of one
additional article in each journal on hand searching. However,
both these articles had already been found prior to the hand search
by searching the reference lists of included articles and review
articles. Therefore, the actual sensitivity for the whole search
process (electronic search plus review of reference lists) was higher
(100.0% (95% CI 46.3–100.0)). Both articles were not identified by
the electronic search as they lacked a term in their title relating to
the biomarker modality used to examine for an association with a
clinical measure of disease progression.
Characteristics of included articles
All included studies except one made the diagnosis of
Alzheimer’s disease using the National Institute of Neurological
and Communicative Disorders and Stroke-Alzheimer’s Disease
and Related Disorders Association (NINCDS-ADRDA) criteria
[9,10]. In two studies the diagnosis was, in at least some
participants, confirmed using neuropathological diagnostic criteria
[19,20].
As illustrated in table 2, almost half of the included studies did
not describe their setting, but the vast majority of those who did
were based in outpatient departments. Similarly, almost a third of
studies failed to mention whether inclusion and exclusion criteria
were applied. Of those providing this information more than three
quarters applied moderately to severely restrictive study entry
criteria.
All of the included studies used an impairment or disability scale
as the clinical measure of disease progression used to test for an
association with a biomarker. None of the studies used measures of
quality of life or handicap as a clinical outcome measure.
Characteristics of study participants
As illustrated in table 2, the median number of study
participants was low at 31 (interquartile range (IQR) 17 to 64).
The mean age of those included was fairly young at 73.0 (standard
deviation (SD) 4.0) years of age, particularly considering that the
median duration of disease at study entry was 3.6 (IQR 2.9 to 4.3)
years.
The majority of participants were not on a cognitive enhancer
at baseline and had mild dementia, as assessed by the MMSE.
Unfortunately, insufficient numbers of studies quoted participants’
baseline scores on other widely used cognitive rating scales to allow
meaningful descriptive statistics relating to these measures to be
calculated.
Quality criteria
The median total score produced by applying the quality
questionnaire to each of the included studies was 7.0 (IQR 6.0 to
7.0) out of a possible 16 (table 1). There was no evidence to suggest
that the quality scores achieved for recently published studies were
better than for those published in the past. In just over half of the
included studies the primary aim was to develop a biomarker for
disease progression. Whilst all studies were rated as having given a
valid reason for choosing the biomarker in question for
investigation, this question was difficult to score for studies whose
primary aim was not to develop a biomarker for disease
progression. In those cases credit was given for a reasonable
explanation of why the studies true aims were scientifically
credible.
The vast majority of studies did not describe the reproducibility
of measuring the biomarker, even in a single centre, and in most
cases no details of the effects of confounding factors on the
biomarker under investigation were described. The majority of
studies did, however, use at least one clinical rating scale examined
in the CCOHTA review. Only three studies undertook a power
calculation to determine the number of participants, and only one
of these recruited the required number of participants.
The median length of follow-up was only 1.0 (IQR 0.8 to 1.7)
years, and most studies only measured the putative biomarker and
clinical measure of disease severity twice (mean number of time-
points 2.3 (SD 0.9)). Unfortunately in a few studies it was
impossible to ascertain exactly how long participants were
followed-up, or how many measurements were taken. Over half
of the included studies also failed to state whether measurement of
the biomarker was undertaken by an operator blind to the
participants’ characteristics.
In most studies over 75% of those entering the study at baseline
completed the follow-up period. However, in many cases it
appeared that analyses were restricted to a select cohort of
patients, drawn from a larger unspecified cohort, who had
Biomarkers for Disease Progression in AD
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completed the study period and, therefore, the true drop-out rate
was probably higher.
Types of biomarkers investigated
The biomarker modalities examined in the 59 included studies
are summarised in table 3, along with details of whether or not a
significant association between each biomarker modality and a
clinical measure of disease progression was demonstrated in each
study. Full details of the individual biomarkers examined in each
study and their relationship with clinical measures of disease
severity are given in tables S1 to S9.
Multiple different candidate biomarkers for disease progression
have been investigated in Alzheimer’s disease, but the majority of
studies examined some form of brain imaging. Those studies
which reported a significant relationship were generally single
studies examining a specific brain region, electrophysiological
feature, blood or CSF constituent, with results which had not been
replicated by other groups. In addition they involved small
numbers of participants. The only biomarkers which appeared to
have sufficient evidence to merit further investigation on the basis
of the evidence presented in tables S1 to S9 were measures of
ventricular volume (associations with MMSE and ADAS-cog) and
whole brain volume (associations with MMSE) made using
magnetic resonance imaging (MRI).
No studies reported an economic analysis of using the
biomarker in question, and nor did any report on the acceptability
of the test to individual patients. Six studies did, to some extent,
examine the effect of symptomatic drug therapy on the biomarker
under examination.
Statistics
Correlation analysis, a basic statistical method which can be
used to examine for a relationship between two variables, was
solely used in 76% (37/49) of the included studies in which a
description of the statistical techniques used was provided. Ten of
the 59 included studies (17%) failed to report what statistical
techniques were employed. Only two studies used a mixed model,
despite the advantages this technique conveys in terms of dealing
with missing data. Only seven (12%) of the included studies made
adjustments for confounding factors. Furthermore, only 14 (24%)
Figure 1. Flow diagram outlining the selection procedure to identify 59 articles which were included in the systematic review of
biomarkers for disease progression in Alzheimer’s disease. Note that of the 20 articles identified by reviewing reference lists, nine were
excluded, and 11 were included in the final qualitative synthesis. Both articles identified by hand searching were included in the final qualitative
synthesis.
doi:10.1371/journal.pone.0088854.g001
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fully reported the outcome of their statistical analyses. Even when
basic correlation analyses were conducted, correlation coefficients
and significance values were often not reported and in no case
were confidence intervals for the correlation coefficient given.
Discussion
We found insufficient evidence to support the current use of any
biomarker to measure disease progression in Alzheimer’s disease
clinical trials. Measurements of ventricular volume and whole
brain volume made by MRI do, however, appear to merit further
investigation.
It is possible that the lack of a current biomarker in Alzheimer’s
disease is because no suitable biomarker exists or, at least, no single
biomarker given the complexity of the disease. However, in
keeping with the findings of our previous systematic review in PD
[8], at present, it probably also reflects the poor quality of studies
which have investigated biomarkers for disease progression. In
order to improve future studies we previously developed a
provisional ‘roadmap’ for conducting biomarker studies primarily
in PD (Figure 2) but this ‘roadmap’ clearly also applies to
Alzheimer’s disease and other neurodegenerative diseases.
The starting point for any disease progression biomarker study
must be a valid reason for selecting a specific biomarker for
investigation based on the pathophysiology of the disease in
question. Unfortunately, the development of a biomarker was not
the primary aim of several studies included in this review; relevant
analyses were simply the by-product of studies with an alternative
aim (e.g. drug development). The appropriateness of studies with
an alternative primary aim undertaking additional analyses to
produce information regarding such associations is questionable.
As our ‘roadmap’ highlights biomarker studies require careful
planning and, therefore, should only run alongside other types of
studies (e.g. long-term prognostic studies or clinical trials) when
either such planning has taken place or as part of the process of
gathering specific preparatory data required for a future formal
biomarker study. Whilst this systematic review could be criticised
for including studies whose primary aim was not to develop a
biomarker for disease progression in Alzheimer’s disease, we did so
to ensure our review was as inclusive as possible and to avoid
missing any potential biomarkers.
Secondly, the reliability of a putative biomarker must be
established by demonstrating the reproducibility of its measure-
ment in a single centre by different personnel, and between
different centres. With imaging biomarkers characterised by a
small change in a small area of the brain reliability of
measurement can be a real issue, particularly between different
Table 2. Study characteristics of the 59 included articles and
baseline characteristics of participants with Alzheimer’s
disease included in those studies.
Setting of included studies
Outpatient 29 49%
Outpatients and inpatients 1 2%
Inpatient 1 2%
Not detailed 28 47%
Inclusion/exclusion criteria applied in
included studies
None 0 0%
Mildly restrictive 5 9%
Moderately restrictive 21 36%
Severely restrictive 15 26%
Not detailed 17 29%
Baseline demographics
Median number of patients 31 (17 to 64)
Mean age (years) 73.0 (4.0)
Mean percentage male 42 (14)
Median disease duration (years) 3.6 (2.9 to 4.3)
Median percentage treated with a cognitive
enhancer
0 (0 to 73)
Baseline disease severity
Median MMSE 21 (20 to 23)
The number and percentage of included studies with each study characteristic
is presented. Means are presented with standard deviations, and medians with
interquartile ranges (IQR).
doi:10.1371/journal.pone.0088854.t002
Table 3. Comparison of the number of included studies investigating a given biomarker modality with the number reporting a
significant association between the biomarker modality and a clinical measure of disease progression.
Biomarker modality
Number of studies investigating
biomarker modality
Number of studies reporting a significant association between
biomarker modality and a clinical measure of disease progression
Brain MRI 17 (29%) 14
CSF 12 (20%) 4
Brain MRS 8 (14%) 8
Serum/plasma/blood 7 (12%) 4
Brain PET 6 (10%) 4
Brain SPECT 5 (9%) 4
Electrophysiology 4 (7%) 3
Brain CT 1 (2%) 1
Ultrasound 1 (2%) 1
Two studies examined for a relationship between two different biomarker modalities (MRI and MRS in one study; MRI and CSF in another study) and a clinical measure
of disease progression. (MRI, magnetic resonance imaging; CSF, cerebrospinal fluid; MRS, magnetic resonance spectroscopy; PET, positron emission tomography; SPECT,
single-photon emission computed tomography; CT, computed tomography).
doi:10.1371/journal.pone.0088854.t003
Biomarkers for Disease Progression in AD
PLOS ONE | www.plosone.org 6 February 2014 | Volume 9 | Issue 2 | e88854
centres which may have different imaging equipment and
software.
Thirdly, an evaluation of the effect of potential confounding
factors on the biomarker (e.g. age, gender, smoking status or
cognitive enhancers) should be undertaken. An understanding of
the influence of these factors on the biomarker will aid sample size
calculations, and allow a rigorous analysis of the final study results
by adjusting for these factors.
In parallel to this pre-study ‘work-up’ of the biomarker the
validity, reliability, and responsiveness, including to clinical
change, of the selected criterion against which a biomarker will
be examined, must be explored. Extensive work has been
undertaken in assessing the validity and reliability of psychometric
instruments [21], and a similar approach here would seem
sensible. Maximising the scientific rigor of the selected criterion is
central to improving the chance of coming to the correct
conclusion about the efficacy of a biomarker for disease
progression, and will have implications for biomarker study
sample size calculations.
Following these initial steps it should then be possible to perform
a power calculation to determine an appropriate sample size
before a biomarker study commences. Sample sizes can be
adjusted to accommodate potential losses to follow-up which, as in
the studies included in this review, are commonly encountered in
longitudinal studies. However, only three studies in this review
performed a power calculation, and only one of these then went on
to recruit sufficient participants. Moreover, the small number of
participants (median 31 (IQR 17 to 64)) in the studies included in
this review is of concern. As studies become smaller it is
increasingly likely that potentially significant associations will not
be detected, and the number of variables which can be included in
multivariate analyses without significantly increasing the risk of
spurious findings becomes limited.
Whilst we only included longitudinal studies in this review it was
clear from filtering the abstracts returned by the electronic search
that, as in PD, numerous cross-sectional disease progression
biomarker studies have been performed in Alzheimer’s disease. As
already discussed, this is not a suitable design to examine for a
relationship between a change in a clinical measure and the
change in a biomarker over time within individuals with
Alzheimer’s disease. The studies included in this review had a
median follow-up duration of only 1.0 (IQR 0.8 to 1.7) years, with
only 44% of studies following participants up for longer than our
chosen discriminator of one year. There is currently no evidence
to suggest what the minimum duration of a disease progression
biomarker study should be, but it obviously needs to be long
enough for a clinically significant change in the criterion, used to
draw associations with the putative biomarker, to be observed.
However, if a short-term change in a biomarker is to be associated
with a long-term change in a clinical outcome measure then
clearly a longer period of follow-up is required. In the included
studies the biomarker and clinical measures were generally only
measured twice (mean 2.3 (SD 0.9) time points). This is clearly
insufficient to allow a linear association to be differentiated from a
non-linear association. Future studies in this area must be
longitudinal and measure the biomarker and clinical measures at
several time points (at least three) over a sufficient follow-up
period, more likely to be measured in years than months, as only
this design will provide sufficient evidence of a biomarkers
potential validity.
The use of moderately to severely restrictive entry criteria in the
majority of studies included in this review will clearly have
influenced the participants’ characteristics. In particular, the
elderly appear to be underrepresented in the included studies.
One American incidence study, for example, found that whilst
Alzheimer’s disease had an annual incidence of 280 per 100,000 in
those aged 65–69 years of age this rose dramatically to 5610 per
100,000 in those over 90 years of age [22]. Similar results have
been reported in other American and European studies [23,24].
This makes the mean age of 73.0 (SD 4.0) years of age of
participants in the studies included in this review concerning,
particularly as the median duration of disease at study entry was
3.6 (IQR 2.9 to 4.3) years. We would recommend that future
studies try to keep their entry criteria as open as possible to
maximise the generalisability of their results.
Reporting of statistical analyses in the included studies was
inadequate. In both correlation and regression analyses, hypoth-
esis testing can be undertaken to determine whether a relationship
exists in the population as a whole, and confidence intervals
calculated to indicate the strength of that relationship. Whilst all
included studies undertook significance testing many failed to
report precise significance values, and instead gave results
descriptively in the text. Whilst this may reflect pressures of space
in published journals, the results should at least be provided as a
supplementary online resource. Several studies unfortunately even
failed to detail what statistical techniques they used. Without clear
reporting of the study methodology, results, and the outcome of
Figure 2. Flow diagram outlining a provisional ‘roadmap’ for
conducting a study to determine whether a given biomarker is
a suitable surrogate for a clinical measure of disease progres-
sion.
doi:10.1371/journal.pone.0088854.g002
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statistical analyses, investigators devalue their study and risk it
being excluded from future systematic reviews or meta-analyses.
The statistical techniques applied in the included studies were in
several cases inappropriate and, more often than not, too
simplistic. There was an overreliance on correlation, which is a
limited technique to examine for a relationship between the
changes in two variables as it only indicates the strength and
direction of a relationship, and does not allow adjustment for
confounding factors [25]. There was a tendency in the included
articles for multiple individual correlation coefficients and
significance values to be calculated after measuring a large
number of variables rather than using a multivariate analysis or a
higher level of statistical modelling (e.g. a linear mixed model
[26]). The majority of studies also failed to adjust for important
confounding factors, regardless of what statistical techniques they
used.
We encountered the same deficiencies in statistical methodol-
ogies in the articles included in our previous systematic review of
biomarkers for disease progression in PD [8], and in that paper
discussed at length potential solutions to these problems. We
strongly recommend that future biomarker studies incorporate a
range of analyses, rather than simply correlation, in order to
explore the validity of more advanced statistical methods. Using
appropriate statistical techniques should reduce the chance of type
I and type II errors and, thereby, allow sensible conclusions to be
drawn about the efficacy of specific biomarkers. Analyses should
be planned and conducted by an experienced statistician given the
complexities of dealing with repeated measures data.
It is pleasing to note that some of the lessons of this systematic
review have already begun to be realised by some researchers and
put into practice. The longitudinal Alzheimer’s Disease Neuroim-
aging Initiative (ADNI) [27] aims to measure various putative CSF
and imaging biomarkers several times over several years. Their
work, like that of the Parkinson’s Progression Markers Initiative
(PPMI) [28] and the Parkinson’s Disease Biomarkers Program
(PDBP) [29], should mark a major shift in the quality of studies of
biomarkers for disease progression, and hopefully lead to advances
in this important field.
Conclusions
This extensive systematic review found insufficient evidence to
recommend the use of any biomarker for measuring disease
progression in Alzheimer’s disease clinical trials. However, further
examination of the efficacy of MRI measurements of ventricular
volume and whole brain volume as biomarkers of disease
progression in Alzheimer’s disease does appear to be merited. As
in our previous systematic in PD, we found methodological,
statistical and reporting flaws in studies examining disease
progression in Alzheimer’s disease. Our methodological guidelines
should hopefully provide a better chance of making progress in this
area, and we would value feedback on them.
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